| dc.contributor.author | Luna Torres, Leydis | spa |
| dc.contributor.author | Contreras Puentes, Neyder | spa |
| dc.contributor.author | Avíz Amador, Antistio | spa |
| dc.date.accessioned | 2021-10-15 00:00:00 | |
| dc.date.available | 2021-10-15 00:00:00 | |
| dc.date.issued | 2021-10-15 | |
| dc.format.mimetype | application/pdf | eng |
| dc.identifier.doi | 10.32997/rcb-2021-3666 | |
| dc.identifier.eissn | 2389-7252 | |
| dc.identifier.issn | 2215-7840 | |
| dc.identifier.url | https://doi.org/10.32997/rcb-2021-3666 | |
| dc.language.iso | eng | eng |
| dc.publisher | Universidad de Cartagena | spa |
| dc.relation.bitstream | https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3666/3029 | |
| dc.relation.citationedition | Núm. 4 , Año 2021 | spa |
| dc.relation.citationendpage | 245 | |
| dc.relation.citationissue | 4 | spa |
| dc.relation.citationstartpage | 234 | |
| dc.relation.citationvolume | 10 | spa |
| dc.relation.ispartofjournal | Revista Ciencias Biomédicas | spa |
| dc.relation.references | Campos-parra AD, Cruz-rico G, Arrieta O. Genotipificación en cáncer de pulmón de células no pequeñas. Gac Mex Oncol. 2012;1(22):35–44. | eng |
| dc.relation.references | Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol. 2017;28(4):784–90. | eng |
| dc.relation.references | Contreras-Puentes N, Mercado-Camargo J, Alvíz-Amador A. In silico study of ginsenoside analogues as possible BACE1 inhibitors involved in Alzheimer’s disease. F1000Research. 2019;8:1169. | eng |
| dc.relation.references | Trott O, Olson AJ. Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. J Comput Chem. 2010;31(2):455–461. | eng |
| dc.relation.references | Dassault Systemes BIOVIA. Discovery Studio Visualizer 4.5 (2016). 2016. | eng |
| dc.relation.references | Fernández Molina JC, Pérez Pérez V. El receptor de EGF (EGFR): una diana terapéutica para el tratamiento den cáncer y sus inhibidores. España; 2006. | eng |
| dc.relation.references | Hanan EJ, Baumgardner M, Bryan MC, Chen Y, Eigenbrot C, Fan P, et al. 4-Aminoindazolyl-dihydrofuro[3,4- d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorganic Med Chem Lett. 2016;26(2):534–9. | eng |
| dc.relation.references | Hanan EJ, Eigenbrot C, Bryan MC, Burdick DJ, Chan BK, Chen Y, et al. Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. J Med Chem. 2014;57(23):10176–91. | eng |
| dc.relation.references | Reiersølmoen AC, Aarhus TI, Eckelta S, Nørsett KG, Sundby E, Hoff BH. Bioorganic Chemistry Potent and selective EGFR inhibitors based on 5-aryl-7 H - pyrrolopyrimidin-. Bioorg Chem. 2019;88:102918. | eng |
| dc.relation.references | Tavakoli F, Ganjalikhany MR. Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase. PLoS One. 2019;14(5):e0217031. | eng |
| dc.relation.references | Lopez Reyes E. Sintesis de precursores para la preparación de acetileno-quinonas, modelos útiles para el estudio de la interacción no covalente del tipo pi/pi. Universidad nacional autónoma de México; 2010. | eng |
| dc.relation.references | Gajiwala KS, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S, et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure. 2013;21(2):209–19. | eng |
| dc.relation.references | European Medicines Agency. Assessment report - Vizimpro. 2019. p. 7–144. | eng |
| dc.relation.references | Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I Dose-escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2011;17(5):1131–9. | eng |
| dc.relation.references | Lavacchi D, Mazzoni F, Giaccone G. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Drug Des Devel Ther. 2019;13:3187–98. | eng |
| dc.relation.references | DongS,LiY,YangH,WuY,LiY,DingC,etal.An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats. 2018;23(11):2894. | eng |
| dc.relation.references | Vishwanathan K, So K, Thomas K, Bramley A, English S, Collier J. Absolute Bioavailability of Osimertinib in Healthy Adults. Clin Pharmacol Drug Dev. 2019;8(2):198–207. | eng |
| dc.relation.references | Planchard D, Brown KH, Wan D, Sang K, Kim W, Ohe Y, et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016;77(4):767–76. | eng |
| dc.relation.references | Schiefer M, Hendriks LEL, Dinh T, Lalji U, Dingemans AC. ScienceDirect Current perspective : Osimertinib- induced QT prolongation : new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018;91:92– 8. | eng |
| dc.relation.references | Xu Z, Li J. Comparative review of drug – drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther. 2019;12:5467–84. | eng |
| dc.relation.references | Macleod AK, Lin D, Huang JTJ, Mclaughlin LA, Henderson CJ, Wolf CR. Cancer Therapy: Preclinical Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. Clin Cancer Res. 2018;24(9):2138–48. | eng |
| dc.relation.references | Sepúlveda JM, Sánchez-gómez P, Ángeles M, Salgado V, Gargini R, Balañá C. Ac ce pt cr t. Expert Opin Investig Drugs. 2018;0(0):1. | eng |
| dc.relation.references | Bello CL, Labadie RR, Ni G, Boutros T, Mccormick C, Ndongo MN. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol. 2012;69(4):991–7. | eng |
| dc.relation.references | Garcia AR, Giri N, Labadie RR, Ni G, Boutros T, Richie N, et al. A Phase I Open ‐ Label Study to Investigate the Potential Drug – Drug Interaction Between Single ‐ Dose Dacomitinib and Steady ‐ State Paroxetine in Healthy Volunteers. J Clin Pharmacol. 2013;54(5):555–462. | eng |
| dc.relation.references | Liam CK. Osimertinib as first-line treatment of EGFR mutant advanced nonsmall- cell lung cancer. Transl Lung Cancer Res. 2017;6(Suppl 1):S62–6. | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | eng |
| dc.rights.creativecommons | Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. | eng |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | eng |
| dc.source | https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3666 | eng |
| dc.subject | EGFR | eng |
| dc.subject | Osimertinib | eng |
| dc.subject | Dacomitinib | eng |
| dc.subject | Docking | eng |
| dc.subject | Tyrosine kinase | eng |
| dc.subject | EGFR | spa |
| dc.subject | Osimertinib | spa |
| dc.subject | Dacomitinib | spa |
| dc.subject | Acoplamiento molecular | spa |
| dc.subject | Tirosina quinasa | spa |
| dc.title | Cribado virtual de Análogos de Osimertinib y Dacomitinib con actividad potencial sobre el receptor de factor de crecimiento epidérmico EGFR (MUTACIONES T790M Y L858R) para el tratamiento del cáncer de pulmón no microcítico | spa |
| dc.title.translated | Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment | eng |
| dc.type | Artículo de revista | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
| dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | eng |
| dc.type.content | Text | eng |
| dc.type.driver | info:eu-repo/semantics/article | eng |
| dc.type.local | Journal article | eng |
| dc.type.redcol | http://purl.org/redcol/resource_type/ART | eng |
| dc.type.version | info:eu-repo/semantics/publishedVersion | eng |
| dspace.entity.type | Publication |
Sede: Claustro de San Agustín, Centro Histórico, Calle de la Universidad Cra. 6 #36-100
Colombia, Bolívar, Cartagena
Ver más...
